Skip to the page content
Your donations
Passes our checks

Jaeb Center for Health Research Inc

EIN 59-3187624 · Tampa, FL

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthWeak38 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

Points to look into

  • It owes more than it owns.

These come from the organization's own tax return. There may be a good explanation; ask the charity.

What it says it does

OUR MISSION IS TO EXPAND SCIENTIFIC KNOWLEDGE AND IMPROVE PUBLIC HEALTH BY DESIGNING AND CONDUCTING WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH.

Income
$58.7 million
Spending
$60.0 million
Spent on programs
86%
Reserves
-1.2 months of spending
Largest source of income
fees for its services, 34%
Employees
187
Volunteers
4
Highest pay
$637,538, medical director

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Weak: 38 out of 100.

  • Reserves

    0 of 35

    Spendable reserves are negative: it owes or has committed more than it holds.

  • Debt

    0 of 20

    It owes 122% of what it owns.

  • Living within its means

    8 of 15

    Spending exceeded income by 2% of income.

  • Income trend

    15 of 15

    Income rose 14% on the year before.

  • Spending floor

    15 of 15

    86% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100.

  • Independent board

    25 of 25

    4 of 5 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. $51.8 million spent. DURING 2025, JCHR WAS ENGAGED IN 61 CLINICAL STUDIES, WHICH CULMINATED IN 53 SCIENTIFIC PUBLICATIONS AND 58 PRESENTATIONS AT PROMINENT NATIONAL AND INTERNATIONAL CONFERENCES. IN 2025, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (6), HELMSLEY CHARITABLE TRUST (7), BREAKTHROUGH T1D (5), FOUNDATION FIGHTING BLINDNESS (6), CYSTIC FIBROSIS FOUNDATION (4), FOOD AND DRUG ADMINISTRATION (1), AND NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH (1). COLLABORATIONS WITH INDUSTRY CONTINUE TO BE AN INTEGRAL PART OF OUR WORK. JCHR WAS ENGAGED IN COLLABORATIONS WITH 14 INDUSTRY PARTNERS SPANNING 21 STUDIES, INCLUDING 11 INVESTIGATOR INITIATED STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), BREAKTHROUGH T1D, HELMSLEY CHARITABLE TRUST, AND ROCHE. JCHR ALSO SELF-FUNDED ONE STUDY AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. AMONG APPROXIMATELY 2,705 ENTITIES RECEIVING NIH FUNDING IN 2025, JCHR RANKS IN THE TOP 8 PERCENT. OUT OF APPROXIMATELY 59,500 NIH GRANTS AWARDED IN 2025, JCHR HAD THE 108TH- (TOP 0.18 PERCENT) AND 202ND - (TOP 0.34 PERCENT) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2025). DURING 2025, JCHR'S RESEARCH EFFORTS FOCUSED ON THREE MAIN THERAPEUTIC AREAS: DIABETES RESEARCH: A MULTITUDE OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES INVOLVED RESEARCH IN TYPE 1, TYPE 2, AND GESTATIONAL DIABETES, ENCOMPASSING PEDIATRIC AND ADULT POPULATIONS INCLUDING MATERNAL-FETAL HEALTH OUTCOMES. MANY STUDIES FOCUSED ON ADVANCING TECHNOLOGY-DRIVEN DIABETES MANAGEMENT WITH ARTIFICIAL PANCREAS SYSTEMS, INSULIN PUMPS, AND CONTINUOUS GLUCOSE MONITORS (CGMS), WHILE OTHERS INVOLVED THE ASSESSMENT OF GROWING ADJUNCT THERAPY USE IN DIABETES CARE AS WELL AS INTERVENTIONAL STRATEGIES TO PRESERVE ENDOGENOUS INSULIN PRODUCTION, UTILIZE INHALED INSULIN, OR LEVERAGE ENHANCED PATIENT AND CAREGIVER EDUCATION INCLUDING AROUND EXERCISE REGIMENS TO IMPROVE GLUCOSE CONTROL. EYE DISEASE RESEARCH: JCHR CONTINUED ITS ROLE AS A COORDINATING CENTER FOR THREE MAJOR NETWORKS AS WELL AS INDIVIDUAL EYE DISEASE STUDIES: 1. THE DRCR RETINA NETWORK, INVESTIGATING DIABETIC RETINOPATHY, AGE-RELATED MACULAR DEGENERATION, AND OTHER RETINAL DISEASES. 2. THE PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG), FOCUSING ON A WIDE RANGE OF CHILDHOOD EYE CONDITIONS. 3. THE FOUNDATION FIGHTING BLINDNESS CONSORTIUM, DEDICATED TO STUDYING RARE RETINAL DISEASES. ADDITIONALLY, JCHR IS CURRENTLY COORDINATING A STUDY ON LONG-TERM OUTCOMES FOLLOWING CORNEAL TRANSPLANTATION. CYSTIC FIBROSIS RESEARCH: JCHR'S GROWING RESEARCH PORTFOLIO INCLUDES A TRIAL INVESTIGATING USE OF THE BIONIC PANCREAS SYSTEM TO MANAGE CYSTIC FIBROSIS-RELATED DIABETES AS WELL AS OBSERVATIONAL STUDIES SEEKING TO BETTER CHARACTERIZE OTHER PHYSIOLOGICAL AND METABOLIC COMPLICATIONS OF CYSTIC FIBROSIS. KEY STUDIES EXAMINED THE IMPACT OF NUTRITION, MUSCLE STRENGTH, AND GLUCOSE MONITORING TECHNOLOGIES ON LUNG FUNCTION AND OVERALL HEALTH OUTCOMES IN INDIVIDUALS WITH CYSTIC FIBROSIS.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since November 1998.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.